Department of Public Health, University Tor Vergata, Catholic University, Rome, Italy.
Clin Infect Dis. 2009 Jan 1;48(1):115-122. doi: 10.1086/593312.
Antiretroviral treatment programs in sub-Saharan Africa have high rates of early mortality and loss to follow-up. Switching to second-line regimens is often delayed because of limited access to laboratory monitoring.
Retrospective analysis was performed of a cohort of adults who initiated a standard first-line antiretroviral treatment at 5 public sector sites in 3 African countries. Monitoring included routine CD4 cell counts, human immunodeficiency virus RNA measures, and records of whether appointments were kept. Incidence and predictors of death, loss to follow-up, and switch to second-line regimens were analyzed by time-to-event approaches.
A total of 3749 patients were analyzed; at baseline, 37.1% were classified as having World Health Organization disease stage 3 or 4, and the median CD4 cell count was 192 cells/mL. First-line regimens were nevirapine based in 96.5% of patients; 17.7% of patients attended <95% of their drug pickup appointments. During 4545 person-years of follow-up, mortality was 8.6 deaths per 100 person-years and was predicted by lower baseline CD4 cell count, lower hemoglobin level, and lower body mass index (calculated as weight in kilograms divided by the square of height in meters); more-advanced clinical stage of infection; male sex; and more missed drug pickup appointments. Dropouts (which accrued at a rate of 2.1 dropouts per 100 person-years) were predicted by a lower body mass index, more missed visits and missed drug pickup appointments, and later calendar year. Incidence of switches to second-line regimens was 4.9 per 100 person-years; increased hazards were observed with lower CD4 cell count and earlier calendar year at baseline. In patients who switched, virological failure was predicted by combined clinical and CD4 criteria with 74% sensitivity and 30% specificity.
In an antiretroviral treatment program employing comprehensive monitoring, the probability of switching to second-line therapy was limited. Regular pickup of medication was a predictor of survival and was also strongly predictive of patient retention.
撒哈拉以南非洲的抗逆转录病毒治疗方案存在较高的早期死亡率和失访率。由于实验室监测受限,二线治疗方案的转换往往会延迟。
对在非洲 3 个国家的 5 个公共卫生部门启动标准一线抗逆转录病毒治疗的成人队列进行回顾性分析。监测包括常规 CD4 细胞计数、人类免疫缺陷病毒 RNA 检测以及是否按时就诊的记录。通过生存时间分析方法分析死亡率、失访率和转换为二线治疗方案的发生率和预测因素。
共分析了 3749 例患者;基线时,37.1%的患者被归类为世界卫生组织疾病分期 3 或 4 期,中位 CD4 细胞计数为 192 个细胞/ml。一线方案中,96.5%的患者采用奈韦拉平;17.7%的患者药物取药预约到诊率<95%。在 4545 人年的随访期间,死亡率为每 100 人年 8.6 例,死亡率的预测因素包括基线 CD4 细胞计数较低、血红蛋白水平较低、体质指数(体重以千克为单位除以身高以米为单位)较低、感染的临床分期较晚、男性和较多的药物取药预约漏失。失访(每 100 人年发生 2.1 例失访)的预测因素包括较低的体质指数、较多的就诊和药物取药预约漏失,以及较晚的日历年份。转换为二线治疗方案的发生率为每 100 人年 4.9 例;在基线时 CD4 细胞计数较低和较早的日历年份观察到转换的风险增加。在转换的患者中,病毒学失败的预测因素是综合临床和 CD4 标准,其敏感性为 74%,特异性为 30%。
在实施全面监测的抗逆转录病毒治疗方案中,转换为二线治疗的可能性有限。按时取药是生存的预测因素,也是患者保留的重要预测因素。